RKDA - Arcadia Biosciences Inc Stock Price, Fair Value and News

2.05USD0.00 (0.00%)Market Closed

Market Summary

USD2.050.00

Market Closed

0.00%

RKDA Stock Price

View Fullscreen

RKDA RSI Chart

RKDA Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

0.51

EV/EBITDA

1.03

Price/Free Cashflow

-0.18

RKDA Price/Sales (Trailing)

RKDA Profitability

EBT Margin

-83.72%

Return on Equity

-108.9%

Return on Assets

-70.96%

Free Cashflow Yield

-547.82%

RKDA Fundamentals

RKDA Revenue

Revenue (TTM)

5.5M

Rev. Growth (Yr)

34.74%

Rev. Growth (Qtr)

-37.23%

RKDA Earnings

Earnings (TTM)

-14.0M

Earnings Growth (Yr)

31.69%

Earnings Growth (Qtr)

-11.04%

Breaking Down RKDA Revenue

Last 7 days

1.0%

Last 30 days

-7.2%

Last 90 days

-14.2%

Trailing 12 Months

-65.9%

How does RKDA drawdown profile look like?

RKDA Financial Health

Current Ratio

4.17

RKDA Investor Care

Shares Dilution (1Y)

43.40%

Diluted EPS (TTM)

-18.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.7M	5.2M	5.2M	5.5M
2022	9.1M	11.5M	10.7M	9.4M
2021	3.5M	4.6M	5.7M	6.8M
2020	1.3M	1.4M	1.3M	2.4M
2019	1.4M	1.2M	1.2M	1.2M
2018	3.2M	2.7M	2.4M	1.5M
2017	3.4M	3.6M	3.1M	4.0M
2016	5.5M	4.7M	4.0M	3.2M
2015	6.4M	6.5M	6.9M	5.4M
2014	0	0	0	7.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcadia Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	schaefer thomas j.	bought	1,442	2.06	700	chief financial officer
Aug 04, 2023	schaefer thomas j.	bought	2,381	3.67	649	chief financial officer
May 30, 2023	jacot stanley jr	bought	21,550	4.31	5,000	chief executive officer
Feb 01, 2023	schaefer thomas j.	bought	161	0.23	700	chief financial officer
Aug 01, 2022	haley pamela	bought	490	0.7	700	chief financial officer
Aug 03, 2020	shultz randall	bought	2,212	3.16	700	chief technology officer
Aug 03, 2020	haley pamela	bought	2,212	3.16	700	chief financial officer
Aug 03, 2020	plavan matthew t	bought	1,848	3.16	585	chief executive officer
Feb 03, 2020	plavan matthew t	bought	1,204	1.72	700	chief executive officer
Feb 03, 2020	reiter sarah	bought	1,204	1.72	700	chief commercial officer

Which funds bought or sold RKDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	new	-	43,939	43,939	-%
Feb 26, 2024	Virtu Financial LLC	new	-	34,000	34,000	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	-	3.00	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-3,523	36,802	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-5.00	55.00	-%
Feb 14, 2024	VitalStone Financial, LLC	unchanged	-	-	-	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	added	197	195,003,000	304,565,000	0.30%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-8.00	119	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-45.00	648	-%

Are Funds Buying or Selling RKDA?

Are funds buying RKDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RKDA

No. of Funds

Unveiling Arcadia Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	58,315	SC 13G/A
Jan 03, 2024	sabby management, llc	8.76%	97,305	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	2,675,409	SC 13G
Jan 20, 2023	moral compass corp	4.6%	1,125,769	SC 13D/A
Feb 11, 2022	intracoastal capital, llc	4.6%	1,058,559	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	3.86%	890,049	SC 13G/A
Feb 10, 2021	hudson bay capital management lp	6.21%	890,049	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	5.3%	745,324	SC 13G/A
Feb 14, 2020	d. e. shaw & co, l.p.	0.2%	13,478	SC 13G/A
Feb 14, 2020	anson funds management lp	2.7%	236,766	SC 13G/A

Recent SEC filings of Arcadia Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	8-K	Current Report
Feb 05, 2024	4	Insider Trading

Peers (Alternatives to Arcadia Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ADM	28.9B	91.7B	-6.61%	-24.60%	9.49	0.31	-10.07%	-31.73%
CAG	14.7B	12.1B	3.85%	-19.47%	15.43	1.21	-0.78%	18.26%
BG	14.7B	61.3B	-0.74%	9.96%	7.7	0.25	-8.91%	30.43%
CPB	13.6B	9.3B	2.83%	-16.33%	17.72	1.46	1.02%	-5.78%
ACI	11.9B	79.2B	-4.85%	-2.90%	9.16	0.15	2.05%	-14.37%
MID-CAP
BRBR	7.3B	1.7B	-6.54%	51.52%	44	4.19	21.49%	39.64%
FLO	5.3B	5.1B	5.01%	-10.35%	42.7	1.04	5.93%	-45.96%
FRPT	5.1B	766.9M	-8.53%	52.82%	-152.11	6.67	28.82%	43.50%
CENT	2.8B	3.3B	-4.39%	42.43%	20.58	0.83	0.37%	-0.15%
CALM	2.7B	2.4B	-5.98%	18.28%	9.76	1.13	-22.17%	-63.60%
SMALL-CAP
ANDE	1.9B	14.8B	-4.24%	22.80%	18.4	0.13	-14.86%	-22.80%
BGS	870.4M	2.1B	-2.97%	-29.98%	-13.15	0.42	-4.65%	-482.22%
BYND	439.8M	343.4M	-18.12%	-49.18%	-1.3	1.28	-18.04%	7.65%
ALCO	215.6M	106.3M	-4.68%	17.81%	4.5	2.03	34.67%	5930.90%
AQB	7.6M	2.5M	-4.95%	255.56%	-0.27	3.06	-21.18%	-24.37%

Arcadia Biosciences Inc News

Latest updates

Arcadia Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-37.2%	1,002,500	1,597,000	1,389,000	1,509,000	744,000	1,570,000	3,858,000	3,220,000	2,047,500	2,376,000	1,860,500	1,345,000	829,500	314,000	281,000	309,000	416,000	392,000	203,000	158,000	444,000
Costs and Expenses	-15.0%	4,113,000	4,839,000	5,180,000	5,557,000	2,891,000	5,561,000	7,641,000	7,843,000	15,975,000	11,089,000	9,088,000	6,154,000	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	11,089,000	9,088,000	6,154,000	-339,000	7,895,000	7,157,000	6,099,000	4,404,500	6,585,000	5,185,000	4,376,000	4,798,000
S&GA Expenses	-8.8%	3,140,500	3,443,000	3,815,000	4,392,000	2,743,000	4,178,000	4,652,000	4,349,000	6,196,000	6,312,000	6,370,000	4,069,000	4,778,000	4,292,000	3,674,000	3,723,000	3,132,500	4,477,000	3,146,000	2,812,000	3,023,000
R&D Expenses	8.9%	332,000	305,000	391,000	359,000	500,000	255,000	359,000	395,000	561,000	1,038,000	1,131,000	1,159,000	1,961,000	1,762,000	1,993,000	2,244,000	1,711,500	1,931,000	1,950,000	1,505,000	1,545,000
EBITDA Margin	54.8%	-0.66	-1.46	-3.03	-2.07	-1.71	-2.04	-2.09	-2.62	-3.51	-4.18	-5.17	-6.82	-9.98	-	-	-	-	-	-	-	-
Interest Expenses	18.0%	157,000	133,000	207,000	198,000	165,500	95,000	30,000	-1,000	-5,000	-15,000	-1,000	9,000	15,000	23,000	6,000	3,000	2,000	3,000	-	-	-
Income Taxes	-	7,000	-	1,000	-	13,000	1,000	-	-	1,000	1,000	-	-	-139,500	9,000	-10,000	17,000	-12,500	-3,000	-1,000	19,000	-16,000
Earnings Before Taxes	-5.3%	-2,616,000	-2,484,000	-	-	2,784,500	-2,287,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	49.3%	-0.84	-1.65	-3.22	-2.18	-1.79	-2.11	-2.15	-2.71	-3.65	-4.35	-5.38	-7.06	-10.26	-	-	-	-	-	-	-	-
Net Income	-11.0%	-2,850,500	-2,567,000	818,000	-9,384,000	-4,173,000	-2,867,000	-3,797,000	-4,610,000	-8,744,000	-2,175,000	-5,422,000	1,681,000	9,052,000	-6,391,000	-9,893,000	2,423,000	-6,243,000	-14,187,000	4,237,000	-12,612,000	-646,000
Net Income Margin	12.9%	-2.54	-2.92	-2.99	-2.63	-1.64	-1.87	-1.68	-2.29	-2.16	0.55	-0.23	-1.58	-1.99	-	-	-	-	-	-	-	-
Free Cashflow	-45.7%	-4,151,000	-2,849,000	-4,839,000	-3,466,000	-2,382,000	-3,371,000	-3,371,000	-4,925,000	-6,748,000	-8,474,000	-6,461,000	-5,192,000	-7,048,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-16.0%	19,705	23,466	26,798	30,410	28,922	34,474	35,008	38,799	43,918	59,228	70,798	70,800	47,348	33,877	37,778	32,248	32,574	37,302	25,346	21,950	24,024
Current Assets	-25.2%	14,972	20,006	23,339	27,205	25,398	30,031	30,058	31,499	35,388	43,834	50,916	56,613	31,696	21,194	26,096	23,758	28,440	33,606	22,000	18,565	22,876
Cash Equivalents	-38.5%	6,518	10,600	13,500	22,998	20,644	22,719	21,200	24,600	28,685	35,500	44,000	32,848	14,042	10,201	14,995	12,973	8,417	20,541	14,646	10,438	11,998
Inventory	-26.3%	1,958	2,657	3,164	2,591	2,321	3,342	3,275	3,235	4,433	5,447	3,897	2,663	3,812	9,416	8,772	5,971	1,794	1,843	839	187	181
Net PPE	-17.9%	384	468	560	622	680	848	954	1,468	2,291	2,634	3,740	3,480	3,539	3,484	3,403	2,540	1,799	1,283	639	460	395
Goodwill	-	-	-	-	-	-	-	-	-	1,240	1,648	1,648	408	408	301	-	-	-	-	-	-	-
Liabilities	-13.2%	7,002	8,068	9,068	13,718	8,022	9,455	8,240	8,557	12,722	19,005	28,119	25,097	18,796	21,875	24,162	20,025	24,248	23,069	17,060	21,317	11,209
Current Liabilities	-7.6%	3,590	3,885	4,091	4,097	4,209	4,051	4,740	4,809	5,040	6,489	7,651	5,617	6,314	8,408	8,364	5,808	5,708	6,023	4,157	2,968	3,054
Long Term Debt	-	-	-	-	-	-	-	-	-	-	78.00	87.00	96.00	2,100	2,548	2,742	-	107	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	78.00	87.00	96.00	2,100	2,548	2,742	-	107	-	-	-	-
Shareholder's Equity	-17.3%	12,841	15,536	17,730	16,692	21,033	25,019	26,768	30,242	31,196	40,223	42,678	45,703	28,552	12,002	13,617	12,223	8,325	14,233	13,542	633	12,815
Retained Earnings	-1.1%	-271,840	-268,987	-266,420	-267,243	-257,859	-253,615	-250,748	-246,971	-226,485	-217,200	-215,027	-209,767	-211,825	-220,725	-214,335	-204,646	-207,171	-200,928	-186,741	-190,978	-178,366
Additional Paid-In Capital	0.1%	284,515	284,371	284,202	284,003	278,827	278,618	277,492	277,169	257,515	257,009	256,616	254,208	239,496	231,954	226,405	215,612	214,826	214,423	194,980	191,566	191,136
Shares Outstanding	15.8%	1,285	1,110	1,108	858	616	575	555	555	555	554	544	474	336	-	-	-	-	-	-	-	-
Minority Interest	0%	-138	-138	-138	-133	-133	-49.00	-39.00	-19.00	103	378	1,039	1,200	827	722	1,496	1,208	621	689	-	-	-
Float	-	-	-	4,169	-	-	-	21,028	-	-	-	53,245	-	-	-	33,300	-	-	-	15,800	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-45.7%	-4,151	-2,849	-4,834	-3,466	-2,356	-3,371	-3,365	-4,885	-6,660	-8,268	-6,233	-4,707	-6,751	-6,919	-7,278	-9,270	-5,012	-3,757	-4,460	-3,969	-2,695
Share Based Compensation	-11.1%	144	162	199	212	203	314	323	260	483	354	356	325	164	500	600	772	417	1,059	389	422	552
Cashflow From Investing	940.0%	52.00	5.00	-4,716	315	281	341	48.00	747	-70.00	-204	17,367	-485	2,856	-181	1,479	13,130	-7,084	-5,497	1,790	2,422	8,025
Cashflow From Financing	-100.0%	-	7.00	-	5,505	-	4,515	-	4.00	-114	21.00	-4.00	21,997	7,736	2,307	9,821	696	-28.00	15,149	6,878	-13.00	-1.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RKDA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 5,330,000	$ 7,418,000
Operating expenses (income):
Cost of revenues	3,300,000	6,101,000
Research and development	1,387,000	1,509,000
Gain on sale of Verdeca	0	(1,138,000)
Impairment of intangible assets	0	141,000
Change in fair value of contingent consideration	0	(70,000)
Gain on sale of property and equipment	(40,000)	(314,000)
Impairment of property and equipment, net	0	160,000
Impairment of ROU asset	113,000	0
Selling, general and administrative	14,508,000	15,036,000
Total operating expenses	19,268,000	21,425,000
Loss from operations	(13,938,000)	(14,007,000)
Interest income	695,000	289,000
Other income, net	48,000	9,000
Valuation loss on March 2023 PIPE	(6,076,000)	0
Change in fair value of common stock warrant and option liabilities	6,544,000	3,209,000
Issuance and offering costs allocated to liability classified options	(430,000)	(314,000)
Net loss from continuing operations before income taxes	(13,157,000)	(10,814,000)
Income tax expense	(8,000)	(14,000)
Net loss from continuing operations	(13,165,000)	(10,828,000)
Net loss from discontinued operations	(821,000)	(4,784,000)
Net loss	(13,986,000)	(15,612,000)
Net loss attributable to non-controlling interest	(5,000)	(236,000)
Net loss attributable to common stockholders	$ (13,981,000)	$ (15,376,000)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders from continuing operations	$ (10.64)	$ (17.67)
Diluted net loss per share attributable to common stockholders from continuing operations	(10.64)	(17.67)
Basic net loss per share attributable to common stockholders from discontinued operations	(0.66)	(7.98)
Diluted net loss per share attributable to common stockholders from discontinued operations	$ (0.66)	$ (7.98)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	1,236,934	599,389
Weighted average shares - Diluted	1,236,934	599,389
Unrealized gains on available-for-sale securities	$ 101,000	$ 0
Other comprehensive income	101,000	0
Comprehensive loss attributable to common stockholders	(13,880,000)	(15,376,000)
Product
Revenues:
Total revenues	5,313,000	6,422,000
License
Revenues:
Total revenues	17,000	879,000
Royalty
Revenues:
Total revenues	$ 0	$ 117,000

RKDA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,518	$ 20,644
Short-term investments	5,124	0
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively	514	1,221
Inventories, net — current	1,958	2,321
Assets held for sale	51	87
Prepaid expenses and other current assets	807	795
Current assets of discontinued operations	0	330
Total current assets	14,972	25,398
Property and equipment, net	384	680
Right of use assets	792	1,848
Inventories, net — noncurrent	3,354	767
Intangible assets, net	39	40
Other noncurrent assets	164	165
Noncurrent assets of discontinued operations	0	24
Total assets	19,705	28,922
Current liabilities:
Accounts payable and accrued expenses	2,410	2,855
Operating lease liability - current	852	1,010
Current liabilities of discontinued operations	0	26
Total current liabilities	3,590	4,209
Operating lease liability - noncurrent	155	1,007
Common stock warrant and option liabilities	1,257	806
Other noncurrent liabilities	2,000	2,000
Total liabilities	7,002	8,022
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.001 par value-150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,285,337 and 616,079 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	65	65
Additional paid-in capital	284,515	278,827
Accumulated other comprehensive income	101	0
Accumulated deficit	(271,840)	(257,859)
Total Arcadia Biosciences stockholders’ equity	12,841	21,033
Non-controlling interest	(138)	(133)
Total stockholders' equity	12,703	20,900
Total liabilities and stockholders’ equity	19,705	28,922
Related Party [Member]
Current liabilities:
Other current liabilities	58	48
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 270	$ 270

About Arcadia Biosciences Inc

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

CEO	Mr. Stanley E. Jacot Jr.
WEBSITE	arcadiabio.com
INDUSTRY	Packaged Foods
EMPLOYEES	30

Arcadia Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Arcadia Biosciences Inc? What does RKDA stand for in stocks?

RKDA is the stock ticker symbol of Arcadia Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcadia Biosciences Inc (RKDA)?

As of Tue Apr 30 2024, market cap of Arcadia Biosciences Inc is 2.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RKDA stock?

You can check RKDA's fair value in chart for subscribers.

What is the fair value of RKDA stock?

You can check RKDA's fair value in chart for subscribers. The fair value of Arcadia Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcadia Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RKDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcadia Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RKDA is over valued or under valued. Whether Arcadia Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcadia Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RKDA.

What is Arcadia Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, RKDA's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 0.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RKDA PE ratio will change depending on the future growth rate expectations of investors.